Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models

Neurobiology of Aging

Volumn 34, Issue 1, 2013, Pages 338-350

  Acker, Christopher M ^a   Forest, Stefanie K ^a   Zinkowski, Ray ^b   Davies, Peter ^a,c   d'Abramo, Cristina ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Pioneer BioSolutions   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Alzheimer's disease; Htau; JNPL3; Sera; Tau transgenic mice; Tau ELISA

Indexed keywords

BIOLOGICAL MARKER; EPITOPE; TAU PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; SENSITIVITY ANALYSIS; SUPERNATANT; TRANSGENIC MOUSE; TREND STUDY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMANS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84868154722     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.05.010     Document Type: Article

References (44)

1. Andorfer C., Acker C.M., Kress Y., Hof P.R., Duff K., Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci 2005, 25:5446-5454.
2. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem 2003, 86:582-590.
3. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
4. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci 2007, 27:9115-9129.
5. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002, 103:26-35.
6. Bancher C., Braak H., Fischer P., Jellinger K.A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett 1993, 162:179-182.
7. Barten D.M., Cadelina G.W., Hoque N., DeCarr L.B., Guss V.L., Yang L., Sankaranarayanan S., Wes P.D., Flynn M.E., Meredith J.E., Ahlijanian M.K., Albright C.F. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J. Alzheimers Dis 2011, 24(Suppl 2):127-141.
8. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
9. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol 2010, 224:472-485.
10. Borchelt D.R., Davis J., Fischer M., Lee M.K., Slunt H.H., Ratovitsky T., Regard J., Copeland N.G., Jenkins N.A., Sisodia S.S., Price D.L. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal 1996, 13:159-163.
11. Boutajangout A., Ingadottir J., Davies P., Sigurdsson E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem 2011, 118:658-667.
12. Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci 2010, 30:16559-16566.
13. Chai X., Wu S., Murray T.K., Kinley R., Cella C.V., Sims H., Buckner N., Hanmer J., Davies P., O'Neill M.J., Hutton M.L., Citron M. Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J. Biol. Chem 2011, 286:34457-34467.
14. Davies P. Characterization and use of monoclonal antibodies to tau and paired helical filament tau. Methods Mol. Med 2000, 32:361-374.
15. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., Burki K., Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis 2000, 7:87-98.
16. Espinoza M., de Silva R., Dickson D.W., Davies P. Differential incorporation of tau isoforms in Alzheimer's disease. J. Alzheimers Dis 2008, 14:1-16.
17. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol 1997, 41:17-24.
18. Greenberg S.G., Davies P., Schein J.D., Binder L.I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem 1992, 267:564-569.
19. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
20. Gu J., Sigurdsson E.M. Immunotherapy for tauopathies. J. Mol. Neurosci 2011, 45:690-695.
21. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol 2003, 60:729-736.
22. Hampel H., Blennow K., Shaw L.M., Hoessler Y.C., Zetterberg H., Trojanowski J.Q. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol 2010, 45:30-40.
23. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett 2001, 297:187-190.
24. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
25. Ihara Y., Nukina N., Miura R., Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem 1986, 99:1807-1810.
26. Jicha G.A., O'Donnell A., Weaver C., Angeletti R., Davies P. Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. J. Neurochem 1999, 72:214-224.
27. Kimura T., Ono T., Takamatsu J., Yamamoto H., Ikegami K., Kondo A., Hasegawa M., Ihara Y., Miyamoto E., Miyakawa T. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 1996, 7:177-181.
28. Lachno D.R., Romeo M.J., Siemers E.R., Vanderstichele H., Coart E., Konrad R.J., Zajac J.J., Talbot J.A., Jensen H.F., Sethuraman G., Demattos R.B., May P.C., Dean R.A. Validation of ELISA Methods for Quantification of Total Tau and Phosporylated-Tau181 in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Disease Studies. J. Alzheimers Dis 2011, 26:531-541.
29. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet 2000, 25:402-405.
30. Lin W.L., Lewis J., Yen S.H., Hutton M., Dickson D.W. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am. J. Pathol 2003, 162:213-218.
31. Lin W.L., Lewis J., Yen S.H., Hutton M., Dickson D.W. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J. Neurocytol 2003, 32:1091-1105.
32. Liu L., Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J. Vis. Exp 2008, (21):e960. 10.3791/960.
33. Murray A., Lawrence G.P. How should the repeatability of clinical measurements be analysed?. An assessment of analysis techniques with data from cardiovascular autonomic function tests. Q. J. Med 1993, 86:831-836.
34. Otvos L., Feiner L., Lang E., Szendrei G.I., Goedert M., Lee V.M. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res 1994, 39:669-673.
35. Polydoro M., Acker C.M., Duff K., Castillo P.E., Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci 2009, 29:10741-10749.
36. Poorkaj P., Kas A., D'Souza I., Zhou Y., Pham Q., Stone M., Olson M.V., Schellenberg G.D. A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm. Genome 2001, 12:700-712.
37. Porstmann T., Kiessig S.T. Enzyme immunoassay techniques. An overview. J. Immunol. Methods 1992, 150:5-21.
38. Riemenschneider M., Wagenpfeil S., Vanderstichele H., Otto M., Wiltfang J., Kretzschmar H., Vanmechelen E., Förstl H., Kurz A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry 2003, 8:343-347.
39. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7737-7741.
40. Tremblay M.A., Acker C.M., Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J. Alzheimers Dis 2010, 19:721-733.
41. Tucker K.L., Meyer M., Barde Y.A. Neurotrophins are required for nerve growth during development. Nat. Neurosci 2001, 4:29-37.
42. Vanderstichele H., De Vreese K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., Hampel H., Bürger K., Parnetti L., Lanari A., Padovani A., DiLuca M., Bläser M., Olsson A.O., Pottel H., Hulstaert F., Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med 2006, 44:1472-1480.
43. Vingtdeux V., Davies P., Dickson D.W., Marambaud P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol 2011, 121:337-349.
44. Zheng-Fischhöfer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem 1998, 252:542-552.